Aurinia director-linked LPs buy 900K common shares

Aurinia Pharmaceuticals Inc. director-associated entities reported significant open-market purchases of common shares.

Rhea-AI Filing Summary

Aurinia Pharmaceuticals Inc. director-associated entities reported significant open-market purchases of common shares. Limited partnerships associated with Kevin Tang bought a total of 900,000 common shares of Aurinia between February 27 and March 3, 2026, in a series of indirect transactions labeled “By LP.”

The purchases were executed at weighted-average prices around the mid-teens per share, with footnotes stating that the trades occurred in multiple transactions within ranges such as $13.51–$14.23 and several other bands in the low-to-mid $14 area. Following these buys, entities associated with Tang were reported as beneficially owning over 12 million Aurinia common shares.

Insider Trade Summary

Net Buyer: 900,000 shares

Net Buy 6 txns

Insider TANG KEVIN

Role Director

Bought 900,000 shs ($12.69M)

Type	Security	Shares	Price	Value
Purchase	Common Shares	184,208	$14.22	$2.62M
Purchase	Common Shares	83,561	$14.33	$1.20M
Purchase	Common Shares	115,792	$14.21	$1.65M
Purchase	Common Shares	300,000	$13.90	$4.17M
Purchase	Common Shares	214,839	$14.12	$3.03M
Purchase	Common Shares	1,600	$14.38	$23K

Holdings After Transaction: Common Shares — 12,229,500 shares (Indirect, By LP)

Footnotes (7)

1. F1. The prices reported are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $13.51 to $14.23. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnotes 1 and 3 through 7.
2. F2. Tang Capital Partners, LP ("TCP") beneficially owns 6,990,461 shares and Tang Capital Partners International, LP ("TCPI") beneficially owns 5,239,039 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP and TCPI.
3. F3. These shares were purchased in multiple transactions ranging from $14.00 to $14.18.
4. F4. These shares were purchased in multiple transactions ranging from $14.35 to $14.61.
5. F5. These shares were purchased in multiple transactions ranging from $14.04 to $14.50.
6. F6. These shares were purchased in multiple transactions ranging from $14.14 to $14.33.
7. F7. These shares were purchased in multiple transactions ranging from $13.97 to $14.39.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider activity did Aurinia Pharmaceuticals (AUPH) report for Kevin Tang?

Aurinia reported that entities associated with director Kevin Tang made indirect open-market purchases totaling 900,000 common shares. These transactions occurred over several days, expanding the limited partnerships’ reported beneficial holdings to more than 12 million Aurinia common shares.

Over what period were the 900,000 Aurinia (AUPH) shares purchased by Tang-affiliated LPs?

The 900,000 Aurinia common shares were purchased between February 27 and March 3, 2026. Multiple open-market transactions took place on those days, each reported with a specific weighted-average price per share and indirect ownership classified as held “By LP.”

At what prices were the Aurinia (AUPH) insider purchases by Tang-related entities executed?

The insider purchases were executed at weighted-average prices in the low-to-mid $14 range. Footnotes note multiple trades within price bands including $13.51–$14.23, $14.00–$14.18, $14.35–$14.61, $14.04–$14.50, $14.14–$14.33, and $13.97–$14.39.

How are the Aurinia (AUPH) shares acquired by Kevin Tang reported in terms of ownership?

The shares are reported as held indirectly, labeled “By LP,” reflecting ownership through Tang Capital Partners, LP and Tang Capital Partners International, LP. Kevin Tang is described as having a pecuniary interest via his role managing the general partner of these limited partnerships.

What is the reported Aurinia (AUPH) beneficial stake of Tang Capital entities after these trades?

Footnotes state that Tang Capital Partners, LP beneficially owns 6,990,461 Aurinia shares and Tang Capital Partners International, LP beneficially owns 5,239,039 shares. Together, these limited partnerships report beneficial ownership exceeding 12 million Aurinia common shares after the disclosed purchases.

Were Kevin Tang’s Aurinia (AUPH) insider transactions open-market purchases or another type?

The transactions are classified as open-market purchases, coded “P” and described as purchases in open market or private transactions. All six reported trades involve common shares acquired indirectly through limited partnerships associated with Kevin Tang.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 05:35 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

TANG KEVIN

(Last) (First) (Middle)

4747 EXECUTIVE DR

SUITE 210

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Aurinia Pharmaceuticals Inc. [ AUPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	02/27/2026		P		300,000	A	$13.9(1)	11,629,500	I	By LP(2)
Common Shares	02/27/2026		P		214,839	A	$14.12(3)	11,844,339	I	By LP(2)
Common Shares	02/27/2026		P		1,600	A	$14.38(4)	11,845,939	I	By LP(2)
Common Shares	03/02/2026		P		83,561	A	$14.33(5)	11,929,500	I	By LP(2)
Common Shares	03/02/2026		P		115,792	A	$14.21(6)	12,045,292	I	By LP(2)
Common Shares	03/03/2026		P		184,208	A	$14.22(7)	12,229,500	I	By LP(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The prices reported are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $13.51 to $14.23. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnotes 1 and 3 through 7.

2. Tang Capital Partners, LP ("TCP") beneficially owns 6,990,461 shares and Tang Capital Partners International, LP ("TCPI") beneficially owns 5,239,039 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP and TCPI.

3. These shares were purchased in multiple transactions ranging from $14.00 to $14.18.

4. These shares were purchased in multiple transactions ranging from $14.35 to $14.61.

5. These shares were purchased in multiple transactions ranging from $14.04 to $14.50.

6. These shares were purchased in multiple transactions ranging from $14.14 to $14.33.

7. These shares were purchased in multiple transactions ranging from $13.97 to $14.39.

	Kevin Tang	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.